NCT02325037 - First-in-Human Single and Multiple Dose of GLPG1837 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Healthy

Interventions

DRUG

GLPG1837 single ascending doses

Single dose, oral suspension

DRUG

Placebo single dose

Single dose, oral suspension matching placebo

DRUG

GLPG1837 multiple ascending doses

Multiple doses, daily for 14 days, oral suspension

DRUG

Placebo multiple doses

Multiple doses, daily for 14 days, oral suspension, matching placebo

Trial Locations (1)

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp